[1] YANG G, DING C S, YANG X, et al. NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer[J]. J Adv Res, 2025, 72: 555-569. doi:  10.1016/j.jare.2024.07.035
[2] CHIDHARLA A, PARSI M, KASI A. Cetuximab[M]. Treasure Island(FL): StatPearls Publishing, 2023.
[3] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi:  10.3410/f.739487650.793592245
[4] MORRIS V K, KENNEDY E B, BAXTER N N, et al. Treatment of metastatic colorectal cancer: ASCO guideline[J]. J Clin Oncol, 2023, 41(3): 678-700. doi:  10.1200/JCO.22.01690
[5] OHSHITA N, ICHIMARU Y, GAMOH S, et al. Management of infusion reactions associated with cetuximab treatment: a case report[J]. Mol Clin Oncol, 2017, 6(6): 853-855. doi:  10.3892/mco.2017.1242
[6] 朱建新, 古今. 西妥昔单抗注射液致严重过敏反应1例[J]. 药物流行病学杂志, 2020, 29(9): 652-653. doi:  10.19960/j.cnki.issn1005-0698.2020.09.012
[7] 国家卫生健康委办公厅. 《新型抗肿瘤药物临床应用指导原则(2024年版)》, 国卫办医政函[2025]2号[EB/OL].(2024-12-31)[2025-11-30]. https://www.nhc.gov.cn/yzygj/c100068/202501/4b86cb63eb03400eb789f371316ecea1.shtml.
[8] NATIONAL CANCER INSTITUTE(NCI). Common Terminology Criteria for Adverse Events(CTCAE)[S]. Version 5.0. 2017.
[9] HANE A, ITO A, ISHIKURA K, et al. Cardiac arrest induced by an anaphylactic reaction associated with the first dose of cetuximab[J]. Cureus, 2022, 14(6): e26351. doi:  10.7759/cureus.26351
[10] HOPPS S, MEDINA P, PANT S, et al. Cetuximab hypersensitivity infusion reactions: Incidence and risk factors[J]. J Oncol Pharm Pract, 2013, 19(3): 222-227. doi:  10.1177/1078155212462440
[11] POINTREAU Y, FRENEAUX C, BEJAN-ANGOULVANT T, et al. Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer[J]. Immunooncol Technol, 2025, 25: 101041. doi:  10.1016/j.iotech.2025.101041
[12] MICHEL S, SCHERER K, HEIJNEN I A F M, et al. Skin prick test and basophil reactivity to cetuximab in patients with IgE to alpha-gal and allergy to red meat[J]. Allergy, 2014, 69(3): 403-405. doi:  10.1111/all.12344
[13] PARK K H, LEE J, BEOM S H, et al. Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection[J]. World Allergy Organ J, 2021, 14(7): 100553. doi:  10.1016/j.waojou.2021.100553
[14] LUNGULESCU CV, UNGUREANU BS, TURCU-STIOLICA A, et al. The role of IgE specific for galactose-α-1, 3-galactose in predicting cetuximab induced hypersensitivity reaction: a systematic review and a diagnostic meta-analysis[J]. Sci Rep. 2020, 10(1): 21355.
[15] 俞苏纯, 毛亚佩, 戴菲菲. 达雷妥尤单抗致3级输注相关反应1例[J]. 药学实践与服务, 2024, 42(2): 86-88.